How big is InspireMD, Inc.?

As of Jun 18, InspireMD, Inc. has a market capitalization of 73.83 million and reported net sales of 7.03 million with a net profit of -36.14 million over the latest four quarters.

Market Cap: As of Jun 18, InspireMD, Inc. has a market capitalization of 73.83 million, categorized as a Micro Cap.<BR><BR>Recent Quarterly Performance: For the latest four quarters, InspireMD, Inc. reported net sales of 7.03 million and a net profit of -36.14 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 36.09 million and total assets of 46.81 million.

What does InspireMD, Inc. do?

InspireMD, Inc. is a medical device company specializing in the MicroNet stent platform for vascular and coronary disease treatment. As of March 2025, it reported net sales of $2 million and a net loss of $11 million, with a market cap of $73.83 million.

Overview: InspireMD, Inc. is a medical device company focused on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: Most recent Net Sales: 2 Million (Quarterly Results - Mar 2025). Most recent Net Profit: -11 Million (Quarterly Results - Mar 2025). Market cap: USD 73.83 Million (Micro Cap).<BR><BR>Key Metrics: P/E: NA (Loss Making). Industry P/E: NA. Dividend Yield: 0.00%. Debt Equity: -0.90. Return on Equity: -127.50%. Price to Book: 2.60.<BR><BR>Contact Details: Address: 4 Menorat Hamaor St., TEL AVIV-YAFO MA: 6744832. Tel: ['1 857 4536553', '1 888 7766804']. Fax: 1 302 6555049. Website: http://www.inspiremd.com/

Should I buy, sell or hold InspireMD, Inc.?

Who are in the management team of InspireMD, Inc.?

As of March 2022, the management team of InspireMD, Inc. includes Chairman Paul Stuka, CEO Marvin Slosman, Independent Vice Chairman Isaac Blech, and Directors Thomas Kester, Gary Roubin, Michael Berman, and Campbell Rogers. They are responsible for the company's strategic direction and operations.

As of March 2022, the management team of InspireMD, Inc. includes the following individuals:<BR><BR>- Mr. Paul Stuka, Chairman of the Board<BR>- Mr. Marvin Slosman, Chief Executive Officer and Director<BR>- Mr. Isaac Blech, Independent Vice Chairman of the Board<BR>- Mr. Thomas Kester, Director<BR>- Dr. Gary Roubin, Director<BR>- Mr. Michael Berman, Independent Director<BR>- Dr. Campbell Rogers, Independent Director<BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

Is InspireMD, Inc. technically bullish or bearish?

As of July 21, 2025, InspireMD, Inc. is in a mildly bearish trend, with daily moving averages indicating bearish momentum, while weekly indicators show mild bullish signals, and the stock has underperformed the S&P 500 over the past month and year.

As of 21 July 2025, the technical trend for InspireMD, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, with key indicators such as the daily moving averages indicating bearish momentum, while the weekly MACD and KST show a mildly bullish signal. The Bollinger Bands are sideways on the weekly and bearish on the monthly, suggesting a lack of strong upward movement. <BR><BR>In terms of performance, the stock has underperformed against the S&P 500 over the past month and year, with returns of -2.81% and -7.98%, respectively, compared to the S&P 500's gains of 2.33% and 17.14%.